▲ Immunisbio / CEOs Kang Jeong-hwa and Hwang Sung-hwan

Immunisbio is a leader in the filed of natural killer cell (NK Cell) in South Korea. The company has capability to run everything that is needed for NK Cell products from research and development to clinical test and production. The researchers at Immunisbio are ambitious to develop new medicines in next 10 years through mechanism of action of immune system analysis and big data.

The World Health Organization reported in 2018 that more than 18 million people suffered from cancer of which 9.6 million died as a result. In South Korea, 8.3% of the total population are reported to have cancer. Rolled up sleeves with the same minded, Immunisbio set sail in 2016 and succeeded commercializing immune cell therapy medicine NK MYJ1633.

In 2018, Immunisbio registered MYJ1633 in Japan and currently is carrying out phase 1/2a clinical tests on colorectal, lung and breast cancers on approval of the Ministry of Food and Drug Safety Korea. MYJ1633 is being sold as medicine to treat stomach, lung and pancreatic cancers in Japan and Vietnam at the moment and a number of contracts are also being made with companies in Malaysia, China and the Philippines. 

For the last 4 and a half years, Immunisbio has obtained 22 trade marks and 12 patents with 4 being in the process. Immunisbio established processing methods of Treg cell mass propagation and activation based on which the company is working on the pipeline of MGY1838. Immunisbio is proud to boast minimized NK Cell damage technology and the shortest culture period to produce cell therapy medicine in South Korea.

"Process automation minimizes manual working-out and it is safer and more economic to develop new medicine. It also reduces the price and helps use GMP-alternative automated cell incubator for mass production" says Kang Jeong-hwa, CEO of Immunisbio. 

Alongside NK Cell products, Immunisbio is expanding the scope of its business to functional cosmetics by releasing CelResto in collaboration with a premium cosmetics company in South Korea. CelResto uses cytokine and MVs to accelerate delivery of bio-signals to improve whitening, wrinkles, inflammation and wound on the skin. All ingredients have passed safety test and registered to the International Cosmetic Ingredient Dictionary. 

"What we do at Immunisbio is to save lives. In other words, we all have a great sense of duty as much as our pride. 80% of staff at Immunisbio are researchers and they are the driving force of our future medicine. We do not see next 1 to 2 years but tens of years ahead where we will sail towards a new world of cell therapy human beings on earth has ever experienced before" says Hwang Sung-hwan, co-CEO of Immunisbio. 

Immunisbio won the technology innovation of the Ministry of SMEs and Startups at the 2020 Innovation Winner. The company is set to go public in 2021. PowerKorea → powering Korean business to the world!